Brainvectis, a French company founded by Nathalie Cartier Lacave in 2015, specializes in gene therapy for neurodegenerative diseases like Alzheimer's and Huntington's. Their approach involves increasing CYP46A1 in the patients' brains to restore cholesterol metabolism, targeting the cholesterol pathway in the brain. By developing these innovative treatments, Brainvectis aims to provide medical practitioners with effective solutions for tackling neurodegenerative diseases.